| LABORATORY-CORPORATION-OF-AMERICA-HOLDINGS |
LABORATORY-CORPORATION-OF-AMERICA-HOLDINGS |
92%
|
Immutep received initial fees from LabCorp in fiscal year 2021 and may be eligible to receive further revenues from commercial milestones as the collaboration progresses under its 2020 License and Co… |
| MERCK-CO-INC |
MERCK-CO-INC |
92%
|
In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase … |
| EOC-PHARMA |
EOC-PHARMA |
90%
|
Immutep granted development and commercialization rights of efti (designated EOC202) in China, Hong Kong, Macau and Taiwan to EOC Pharma. |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from MRK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
ure as more patients are recruited to our clinical trials. In particular, we expect to continue to incur significant losses in carrying out clinical trials of efti and IMP761 as well as from ongoing … |
| AMERICA-HOLDINGS |
AMERICA-HOLDINGS |
62%
|
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio… |
| DELAWARE-UNITED-STATES-IMMUTEP-GMBH |
DELAWARE-UNITED-STATES-IMMUTEP-GMBH |
62%
|
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio… |
| FORMATION-ACQUISITION-JURISDICTION-IMMUTEP-U-S-I |
FORMATION-ACQUISITION-JURISDICTION-IMMUTEP-U-S-I |
62%
|
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio… |
| GERMANY-IMMUTEP-AUSTRALIA-PTY-LTD |
GERMANY-IMMUTEP-AUSTRALIA-PTY-LTD |
62%
|
nd first-in-human Phase I study evaluating IMP761. In June 2025, Immutep announced initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppressio… |
| IMMUTEP-AUSTRALIA-PTY-LTD |
IMMUTEP-AUSTRALIA-PTY-LTD |
62%
|
NOTE 25. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.… |
| IMMUTEP-GMBH |
IMMUTEP-GMBH |
62%
|
NOTE 25. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.… |
| IMMUTEP-IP-PTY-LTD |
IMMUTEP-IP-PTY-LTD |
62%
|
NOTE 25. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.… |
| IMMUTEP-U-S-INC |
IMMUTEP-U-S-INC |
62%
|
th respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny st… |
| IMMUTEP-US-INC |
IMMUTEP-US-INC |
62%
|
NOTE 25. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.… |
| PRIMA-BIOMED-LTD |
PRIMA-BIOMED-LTD |
62%
|
th respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny st… |
| PRR-MIDDLE-EAST-FZ-LLC |
PRR-MIDDLE-EAST-FZ-LLC |
62%
|
NOTE 24. REMUNERATION OF AUDITORS During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms.… |
